The three major U.S. stock indexes were mixed overnight, with the Dow closing higher, and the Nasdaq and S&P 500 closing lower. As of 11:16 on January 31, 2024, S&P Biotech ETF (159502) exceeded 2% intraday**, with a turnover rate of 1384%, active trading on the market. In terms of fund inflows, S&P Biotech ETF has had a net inflow for 11 consecutive days, with a single-day net inflow of 58.9 million yuan yesterday.
The S&P Biotech ETF (159502) tracks the S&P Biotech Select Sector and tracks the same index as the well-known U.S. Biotech ETF (XBI), making it the only ETF in A-shares to track the index.
On the news side, the NMPA approved the marketing application of Novo Nordno and Xin (semaglutide tablets) in China for **type 2 diabetes**. Novo Nordisk solves the problem of gastrointestinal absorption of peptide drugs through oral administration with the innovative technology of "SNAC absorption promoter", which can increase the molecular bioavailability of semaglutide by about 100 times in the oral route of administration, achieving a historic leap in the oral route of GLP-1RA.
Some industry insiders believe that the improvement of the global investment and financing environment, the innovation of new products in the industry, and some blockbuster mergers and acquisitions will largely drive the index**. And based on the fact that the FOMC interest rate hike is nearing its end, the global investment climate is picking up, the emergence of blockbuster new products, and the market has fully digested the previous risks, it is a good time to deploy the biotech sector now.
The above content and data have nothing to do with the position of the interface and do not constitute investment advice. Do so at your own risk.